The first and only FDA-approved pill proven to increase a woman’s sex drive.

The drug modulates the brain pathways involved in sexual response. After 3 days of taking the medication, there is a steady level of the drug in the body. However, some people do not metabolize CYP2C19, an enzyme protein, effectively, and this can cause levels of the drug to build up, resulting in side effects. Vyleesi lasts around 2.7 hours, and the average time it takes to clear the body is 6.5 hours.

• The pharmacology of flibanserin demonstrates a complex serotonin-dopamine interplay.
• The medication is not a substitute for addressing relationship or psychological factors.
• It is essential to evaluate contraindications before prescribing flibanserin.
• The drug's societal impact includes increased awareness of female sexual health.
• Use during pregnancy is contraindicated due to unknown risks.
• Flibanserin requires healthcare provider supervision due to its safety profile.
• Its effectiveness varies, necessitating personalized treatment approaches.
• Ongoing studies seek to expand understanding of its benefits and risks.
• The medication represents a milestone in female sexual medicine advancements.

The drug may slow how fast the body can process other medication.

Brand names

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs). This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively. RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases. Vyleesi and Addyi treat FSIAD in premenopausal people. No research has tested the drug in people during or after menopause. The medications may be beneficial for premenopausal people who: Factors that are lined with a reduced sex drive in females include: certain health conditions, such as diabetes and heart disease The FDA-approved drugs for FSIAD can have the following side effects.

The side effects of Addyi can include: those who have consumed alcohol in the last 2 hours The drug can cause severe low blood pressure and fainting in people who take it with alcohol or who have liver conditions. irritation or a rash at the injection site darkening of the skin, resulting in dark spots called hyperpigmentation on the gums, face and breasts Vyleesi may reduce the efficiency of oral medications due to slower emptying of the gastric system. It can also make drugs containing naltrexone to treat alcohol and opioid addiction less effective, so anyone taking a drug that contains naltrexone should avoid Vyleesi.

• Flibanserin's mechanism involves increasing dopamine and norepinephrine and decreasing serotonin levels.
• It does not address libido caused by relationship issues or physical health problems.
• Flibanserin was once controversial due to debates over its effectiveness.
• It is not suitable for women taking certain antidepressants due to drug interactions.
• The medication has warnings for severe hypotension and syncope.
• Patients are advised to avoid alcohol consumption completely while on the drug.
• Flibanserin's approval was considered a breakthrough for female sexual health.
• Insurance coverage for flibanserin varies and can be limited.
• The drug's marketing emphasizes the importance of patient counseling.

Like other drugs, Vyleesi and Addyi can cause allergic reactions. Seek immediate medical help if symptoms of an allergic reaction or anaphylaxis occur. A person should speak with a doctor before taking any supplements to boost libido. The doctor can advise on the suitabilty of the products, and they may recommend medications such as Addyi and Vyleesi. Vyleesi (bremelanotide) and Addyi (flibanserin) can help treat female sexual interest/arousal disorder (FSIAD) in premenopausal people. The FDA has not approved Viagra for use in females. The FDA also advises against taking over-the-counter supplements that are marketed to boost libido. Medication may not treat all causes of low sexual desire.

A person can contact a doctor fildena super active 100 for advice on suitable medications and other ways to help improve their libido.

What side effects can this medication cause?

Vyleesi (bremelanotide) and Addyi (flibanserin) can help treat female sexual interest/arousal disorder (FSIAD) in premenopausal people. The FDA has not approved Viagra for use in females. The FDA also advises against taking over-the-counter supplements that are marketed to boost libido. Medication may not treat all causes of low sexual desire. A person can contact a doctor fildena super active 100 for advice on suitable medications and other ways to help improve their libido.

FDA-approved indications

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire. The FDA has approved Addyi (flibanserin 100 mg) for the treatment of hypoactive sexual desire disorder (HSDD) in women younger than 65 years, according to an announcement from Sprout Pharmaceuticals. The decision expands the drug’s original indication and represents the first FDA approval specifically extending pharmacologic treatment options for postmenopausal women with HSDD. HSDD is characterized by a persistent lack of sexual interest or desire that causes distress and is not better explained by another medical or psychiatric condition. It is considered the most common form of sexual dysfunction in women, with estimates suggesting that approximately 40% of women experience symptoms consistent with low sexual desire at some point in their lives.

Sample Use Guides

Despite its prevalence, treatment options have historically been limited, particularly for postmenopausal women. “This milestone reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized,” said Cindy Eckert, founder and CEO of Sprout Pharmaceuticals. “Over the years, we’ve pushed for the science to speak louder than the stigma—and today’s approval shows how far we’ve come. I want to congratulate the FDA for recognizing what millions of women have long deserved: equitable, science-backed care at every stage of life.” Addyi was initially approved by the FDA in 2015 for the treatment of HSDD in premenopausal women. The medication is a nonhormonal, centrally acting agent that modulates key neurotransmitters involved in sexual response. The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire.

What should I know about storage and disposal of this medication?

The drug modulates the brain pathways involved in sexual response. After 3 days of taking the medication, there is a steady level of the drug in the body. However, some people do not metabolize CYP2C19, an enzyme protein, effectively, and this can cause levels of the drug to build up, resulting in side effects. Vyleesi lasts around 2.7 hours, and the average time it takes to clear the body is 6.5 hours. The drug may slow how fast the body can process other medication.

What do I need to tell my doctor BEFORE I take this drug?

Vyleesi and Addyi treat FSIAD in premenopausal people. No research has tested the drug in people during or after menopause. The medications may be beneficial for premenopausal people who: Factors that are lined with a reduced sex drive in females include: certain health conditions, such as diabetes and heart disease The FDA-approved drugs for FSIAD can have the following side effects. The side effects of Addyi can include: those who have consumed alcohol in the last 2 hours The drug can cause severe low blood pressure and fainting in people who take it with alcohol or who have liver conditions. irritation or a rash at the injection site darkening of the skin, resulting in dark spots called hyperpigmentation on the gums, face and breasts Vyleesi may reduce the efficiency of oral medications due to slower emptying of the gastric system.

Brand Names: US

It can also make drugs containing naltrexone to treat alcohol and opioid addiction less effective, so anyone taking a drug that contains naltrexone should avoid Vyleesi. Like other drugs, Vyleesi and Addyi can cause allergic reactions. Seek immediate medical help if symptoms of an allergic reaction or anaphylaxis occur. A person should speak with a doctor before taking any supplements to boost libido. The doctor can advise on the suitabilty of the products, and they may recommend medications such as Addyi and Vyleesi. The FDA has approved Addyi (flibanserin 100 mg) for the treatment of hypoactive sexual desire disorder (HSDD) in women younger than 65 years, according to an announcement from Sprout Pharmaceuticals. The decision expands the drug’s original indication and represents the first FDA approval specifically extending pharmacologic treatment options for postmenopausal women with HSDD. HSDD is characterized by a persistent lack of sexual interest or desire that causes distress and is not better explained by another medical or psychiatric condition. It is considered the most common form of sexual dysfunction in women, with estimates suggesting that approximately 40% of women experience symptoms consistent with low sexual desire at some point in their lives. Despite its prevalence, treatment options have historically been limited, particularly for postmenopausal women. “This milestone reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized,” said Cindy Eckert, founder and CEO of Sprout Pharmaceuticals. “Over the years, we’ve pushed for the science to speak louder than the stigma—and today’s approval shows how far we’ve come. I want to congratulate the FDA for recognizing what millions of women have long deserved: equitable, science-backed care at every stage of life.” Addyi was initially approved by the FDA in 2015 for the treatment of HSDD in premenopausal women. The medication is a nonhormonal, centrally acting agent that modulates key neurotransmitters involved in sexual response.

Side effects

“Menopause does not mark the end of a woman’s sexuality, but for too long, medicine has treated it that way,” vardenafil 10 mg tablet Haver said. “This FDA approval is a long-overdue recognition that postmenopausal women deserve evidence-based treatment options for low sexual desire. Expanding Addyi’s approval is historic in validating women’s experiences and ensuring that millions of women suffering have real choices when it comes to their sexual health.” Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in postmenopausal women. aDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh bDepartment of Endocrinology, North East Medical College and Hospital, Sylhet, Bangladesh cDepartment of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh dDepartment of Gyne & Obs, Khaliajuri Upazila Health Complex, Netrokona, Bangladesh eDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India fDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh gDepartment of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India. Received: 19 March 2024 / Received in final form: 23 May 2024 / Accepted: 24 May 2024 The authors have no funding and conflicts of interest to disclose.

What are some other side effects of this drug?

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Supplemental Digital Content is available for this article. How to cite this article: Kamrul-Hasan ABM, Hannan MA, Alam MS, Aalpona FTZ, Nagendra L, Selim S, Dutta D. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis. Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh Sadar, Mymensingh 2200, Bangladesh (e-mail: [email protected]). Since its original approval, its safety and efficacy profile has been evaluated in extensive clinical development programs, which Sprout described as the largest and most rigorous clinical trials conducted in women’s sexual health. The current approval follows the FDA’s decision earlier this year to grant priority review status to the expanded indication.

StatPearls [Internet].

The primary outcomes were the changes from baseline in satisfying sexual events (SSE) per month and sexual desire score per month measured using an electronic diary (eDiary). From 478 initially screened articles, data from 8 RCTs involving 7906 women with HSDD were analyzed. In premenopausal women, flibanserin 100 mg was superior to placebo in improving the number of SSE per month (mean difference, MD 0.69, 95% CI [0.39, 0.99]), eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (FSFI-d) score (MD 0.30, 95% CI [0.29, 0.31]), FSFI total score (MD 2.51, 95% CI [1.47, 3.55]), Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD −0.30, 95% CI [−0.31, −0.29]), and FSDS-R total score (MD −3.30, 95% CI [−3.37, −3.23]). Priority review is reserved for therapies that may provide significant improvements in the treatment of serious conditions or address unmet medical needs. According to the company, the designation and subsequent approval reflect increasing regulatory attention to gaps in women’s health care.

• Flibanserin is classified as a centrally acting serotonergic agent.
• It is not a testosterone-based therapy, unlike some other treatments.
• The FDA approval was based on studies showing increased sexual desire in women.
• The medication can cause sleep disturbances, including somnolence.
• Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
• It is recommended to start treatment at least 4 weeks before expecting improvement.
• Discontinuation of the drug normally leads to the loss of effects.
• The drug's efficacy is modest compared to some male sexual dysfunction drugs.
• Initiation of therapy involves screening for contraindications.

“This is a major shift in expanding awareness and access to treatment for HSDD—a condition that is both common and profoundly undertreated—and we’re grateful that the FDA has acknowledged the importance of closing this gap in women’s sexual health care,” Eckert added. Clinicians who specialize in sexual medicine and menopause care have described the expanded approval as an important step for patients who previously lacked FDA-approved treatment options. Rachel Rubin, MD, a urologist and sexual medicine specialist, highlighted the clinical implications for postmenopausal patients. “I was in the room a decade ago when Addyi became the historic first for women’s sexual health, and I have been waiting for this moment ever since,” Rubin said. “So many of my postmenopausal patients have carried the weight of frustrating low sexual desire with no FDA-approved option to turn to. It’s a critical acknowledgment that their pleasure, their well-being, and their quality of life matter—and that science-backed care should be available to every woman, at every stage of her life.” International regulatory decisions preceded the US approval. In 2021, Health Canada authorized the use of flibanserin in postmenopausal women, a move that Sprout cited as an important step toward the current FDA action. With the expanded US indication, Addyi is now approved for women younger than 65 years, making it the first and only FDA-approved pharmacologic therapy for HSDD across this broader age range. Sprout Pharmaceuticals stated that Addyi has been prescribed by more than 30,000 US health care professionals to date. The company emphasized that appropriate patient selection and counseling remain essential and that patients should consult with their physicians to determine whether treatment is appropriate. Mary Claire Haver, MD, an obstetrician-gynecologist and menopause specialist, also emphasized the broader clinical context of the approval.

Availability and cost

Since its original approval, its safety and efficacy profile has been evaluated in extensive clinical development programs, which Sprout described as the largest and most rigorous clinical trials conducted in women’s sexual health. The current approval follows the FDA’s decision earlier this year to grant priority review status to the expanded indication. Priority review is reserved for therapies that may provide significant improvements in the treatment of serious conditions or address unmet medical needs. According to the company, the designation and subsequent approval reflect increasing regulatory attention to gaps in women’s health care. “This is a major shift in expanding awareness and access to treatment for HSDD—a condition that is both common and profoundly undertreated—and we’re grateful that the FDA has acknowledged the importance of closing this gap in women’s sexual health care,” Eckert added.

Incidence not known

Clinicians who specialize in sexual medicine and menopause care have described the expanded approval as an important step for patients who previously lacked FDA-approved treatment options. Rachel Rubin, MD, a urologist and sexual medicine specialist, highlighted the clinical implications for postmenopausal patients. “I was in the room a decade ago when Addyi became the historic first for women’s sexual health, and I have been waiting for this moment ever since,” Rubin said. “So many of my postmenopausal patients have carried the weight of frustrating low sexual desire with no FDA-approved option to turn to. It’s a critical acknowledgment that their pleasure, their well-being, and their quality of life matter—and that science-backed care should be available to every woman, at every stage of her life.” International regulatory decisions preceded the US approval.

What should I tell my healthcare provider before using Addyi?

In 2021, Health Canada authorized the use of flibanserin in postmenopausal women, a move that Sprout cited as an important step toward the current FDA action. With the expanded US indication, Addyi is now approved for women younger than 65 years, making it the first and only FDA-approved pharmacologic therapy for HSDD across this broader age range. Sprout Pharmaceuticals stated that Addyi has been prescribed by more than 30,000 US health care professionals to date. The company emphasized that appropriate patient selection and counseling remain essential and that patients should consult with their physicians to determine whether treatment is appropriate. Mary Claire Haver, MD, an obstetrician-gynecologist and menopause specialist, also emphasized the broader clinical context of the approval. “Menopause does not mark the end of a woman’s sexuality, but for too long, medicine has treated it that way,” vardenafil 10 mg tablet Haver said.

• Summary: A daily, non-hormonal pill for premenopausal women with HSDD.
• Key benefit: Modest increase in sexual desire and satisfying events for some.
• Key risk: Potentially severe interactions with alcohol and many medications.
• Management: Strict adherence to REMS, bedtime dosing, and no alcohol.
• Patient profile: Premenopausal woman with distress from low desire, otherwise healthy.
• Provider role: Certify, counsel, monitor, and manage expectations.
• Place in therapy: One option among a comprehensive approach to sexual health.
• Public health impact: Highlighted need for and challenges in female sexual medicine.
• Future: Continued evaluation of real-world outcomes and safety profile.

“This FDA approval is a long-overdue recognition that postmenopausal women deserve evidence-based treatment options for low sexual desire. Expanding Addyi’s approval is historic in validating women’s experiences and ensuring that millions of women suffering have real choices when it comes to their sexual health.” Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in postmenopausal women. aDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh bDepartment of Endocrinology, North East Medical College and Hospital, Sylhet, Bangladesh cDepartment of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh dDepartment of Gyne & Obs, Khaliajuri Upazila Health Complex, Netrokona, Bangladesh eDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India fDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh gDepartment of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India. Received: 19 March 2024 / Received in final form: 23 May 2024 / Accepted: 24 May 2024 The authors have no funding and conflicts of interest to disclose. All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Supplemental Digital Content is available for this article. How to cite this article: Kamrul-Hasan ABM, Hannan MA, Alam MS, Aalpona FTZ, Nagendra L, Selim S, Dutta D. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis. Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh Sadar, Mymensingh 2200, Bangladesh (e-mail: [email protected]). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs). This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively.

RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases. The primary outcomes were the changes from baseline in satisfying sexual events (SSE) per month and sexual desire score per month measured using an electronic diary (eDiary). From 478 initially screened articles, data from 8 RCTs involving 7906 women with HSDD were analyzed.

In premenopausal women, flibanserin 100 mg was superior to placebo in improving the number of SSE per month (mean difference, MD 0.69, 95% CI [0.39, 0.99]), eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (FSFI-d) score (MD 0.30, 95% CI [0.29, 0.31]), FSFI total score (MD 2.51, 95% CI [1.47, 3.55]), Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD −0.30, 95% CI [−0.31, −0.29]), and FSDS-R total score (MD −3.30, 95% CI [−3.37, −3.23]).